NMR structure of the Wnt modulator protein Sclerostin

Biochemical and Biophysical Research Communications

Volumn 380, Issue 1, 2009, Pages 160-165

  Weidauer, Stella E ^a   Schmieder, Peter ^b   Beerbaum, Monika ^b   Schmitz, Werner ^a   Oschkinat, Hartmut ^b   Mueller, Thomas D ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

Bone metabolism; Cystin knot; LRP5; NMR structure; SOST; Wnt antagonist

Indexed keywords

SCLEROSTIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

MURINAE;

EID: 59649096700     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.01.062     Document Type: Article

References (23)

1. Stein S.A., Witkop C., Hill S., Fallon M.D., Viernstein L., Gucer G., McKeever P., Long D., Altman J., Miller N.R., Teitelbaum S.L., and Schlesinger S. Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology 33 (1983) 267-277
2. van Buchem F.S., Hadders H.N., and Ubbensx R. An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol. 44 (1983) 109-120
3. Balemans W., Patel N., Ebeling M., van Hul E., Wuyts W., Lacza C., Dioszegi M., Dikkers F.G., Hildering P., Willems P.J., Verheij J.B., Lindpaintner K., Vickery B., Foernzler D., and van Hul W. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39 (2002) 91-97
4. Brunkow M.E., Gardner J.C., van Ness J., Paeper B.W., Kovacevich B.R., Proll S., Skonier J.E., Zhao L., Sabo P.J., Fu Y., Alisch R.S., Gillett L., Colbert T., Tacconi P., Galas D., Hamersma H., Beighton P., and Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68 (2001) 577-589
5. Balemans W., Ebeling M., Patel N., van Hul E., Olson P., Dioszegi M., Lacza C., Wuyts W., van Den Ende J., Willems P., Paes-Alves A.F., Hill S., Bueno M., Ramos F.J., Tacconi P., Dikkers F.G., Stratakis C., Lindpaintner K., Vickery B., Foernzler D., and van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10 (2001) 537-543
6. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Lowik C.W., and Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19 (2005) 1842-1844
7. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., Hamersma H., Papapoulos S.E., ten Dijke P., and Lowik C.W. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199 (2004) 805-814
8. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., Shpektor D., Jonas M., Kovacevich B.R., Staehling-Hampton K., Appleby M., Brunkow M.E., and Latham J.A. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22 (2003) 6267-6276
9. Sutherland M.K., Geoghegan J.C., Yu C., Turcott E., Skonier J.E., Winkler D.G., and Latham J.A. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35 (2004) 828-835
10. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., Harris S.E., and Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. (2005)
11. Semenov M., Tamai K., and He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280 (2005) 26770-26775
12. Ellies D.L., Viviano B., McCarthy J., Rey J.P., Itasaki N., Saunders S., and Krumlauf R. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res. 21 (2006) 1738-1749
13. Semenov M.V., and He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem. 281 (2006) 38276-38284
14. Deal C. Potential new drug targets for osteoporosis. Nat. Clin. Pract. Rheumatol. 5 (2009) 20-27
15. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., Kurahara C., Gao Y., Cao J., Gong J., Asuncion F., Barrero M., Warmington K., Dwyer D., Stolina M., Morony S., Sarosi I., Kostenuik P.J., Lacey D.L., Simonet W.S., Ke H.Z., and Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23 (2008) 860-869
16. Veeman M.T., Slusarski D.C., Kaykas A., Louie S.H., and Moon R.T. Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr. Biol. 13 (2003) 680-685
17. Cavanagh J. Protein NMR Spectroscopy: Principles and Practice (1996), Academic Press, San Diego
18. Cornilescu G., Delaglio F., and Bax A. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J. Biomol. NMR 13 (1999) 289-302
19. Schwieters C.D., Kuszewski J.J., and Clore G.M. Using Xplor-NIH for NMR molecular structure determination. Prog. Nucl. Magn. Reson. Spectrosc. 48 (2006) 47-62
20. Wishart D.S., and Sykes B.D. The C-13 chemical-shift index - a simple method for the identification of protein secondary structure using C-13 chemical-shift data. J. Biomol. NMR 4 (1994) 171-180
21. Wishart D.S., Sykes B.D., and Richards F.M. The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry 31 (1992) 1647-1651
22. Sippl M.J., and Wiederstein M. A note on difficult structure alignment problems. Bioinformatics 24 (2008) 426-427
23. Avsian-Kretchmer O., and Hsueh A.J. Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol. Endocrinol. 18 (2004) 1-12